Pub Date : 2022-09-29eCollection Date: 2022-07-01DOI: 10.1055/a-1929-5265
Nicola Hazel Guy
There is a range of differential diagnoses for intramedullary lesions of the conus medullaris, both neoplastic and non-neoplastic. There is a limited role for surgery in a large proportion of these diagnoses, and operative risks can outweigh any benefits of surgery. Here a case is presented of a patient referred to a neurosurgical center for a biopsy of a presumed neoplastic conus tumor. However, through the collaboration of a multidisciplinary team, further diagnoses were considered. After thorough investigation, two conditions were diagnosed: venous congestive myelopathy secondary to inferior vena cava agenesis and spinal neurosarcoidosis. This case demonstrates the importance of neurosurgeons retaining a high degree of suspicion for alternative diagnosis to avoid unnecessary surgical risk.
{"title":"Acute Venous Congestive Myelopathy in a Patient with Neurosarcoidosis.","authors":"Nicola Hazel Guy","doi":"10.1055/a-1929-5265","DOIUrl":"https://doi.org/10.1055/a-1929-5265","url":null,"abstract":"<p><p>There is a range of differential diagnoses for intramedullary lesions of the conus medullaris, both neoplastic and non-neoplastic. There is a limited role for surgery in a large proportion of these diagnoses, and operative risks can outweigh any benefits of surgery. Here a case is presented of a patient referred to a neurosurgical center for a biopsy of a presumed neoplastic conus tumor. However, through the collaboration of a multidisciplinary team, further diagnoses were considered. After thorough investigation, two conditions were diagnosed: venous congestive myelopathy secondary to inferior vena cava agenesis and spinal neurosarcoidosis. This case demonstrates the importance of neurosurgeons retaining a high degree of suspicion for alternative diagnosis to avoid unnecessary surgical risk.</p>","PeriodicalId":44256,"journal":{"name":"Journal of Neurological Surgery Reports","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/98/74/10-1055-a-1929-5265.PMC9522485.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40392967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-20eCollection Date: 2022-07-01DOI: 10.1055/s-0042-1754320
David J Mazur-Hart, Brannan E O'Neill, Brandi W Pang, Melanie H Hakar, Matthew D Wood, Sachin Gupta, Christina M Sayama, Jesse J Liu, Aclan Dogan
Objective We describe the first jugular foramen angiomatoid fibrous histiocytoma (AFH) case and the first treatment with preoperative endovascular embolization. AFH is a rare intracranial neoplasm, primarily found in pediatric patient extremities. With an increase in AFH awareness and a well-described genetic profile, intracranial prevalence has also subsequently increased. Study Design We compare this case to previously reported cases using PubMed/Medline literature search, which was performed using the algorithm ["intracranial" AND "angiomatoid fibrous histiocytoma"] through December 2020 (23 manuscripts with 46 unique cases). Patient An 8-year-old female presented with failure to thrive and right-sided hearing loss. Work-up revealed an absence of right-sided serviceable hearing and a large jugular foramen mass. Angiogram revealed primary arterial supply from the posterior branch of the ascending pharyngeal artery, which was preoperatively embolized. Intervention Gross total resection was performed via a translabyrinthine approach. Conclusion The case presented is unique; the first reported AFH at the jugular foramen and the first reported case utilizing preoperative embolization. Preoperative embolization is a relatively safe technique that can improve the surgeon's ability to perform a maximally safe resection, which may decrease the need for adjuvant radiation in rare skull base tumors in young patients.
{"title":"Operative Technique: Angiomatoid Fibrous Histiocytoma-Unique Case and Management.","authors":"David J Mazur-Hart, Brannan E O'Neill, Brandi W Pang, Melanie H Hakar, Matthew D Wood, Sachin Gupta, Christina M Sayama, Jesse J Liu, Aclan Dogan","doi":"10.1055/s-0042-1754320","DOIUrl":"https://doi.org/10.1055/s-0042-1754320","url":null,"abstract":"<p><p><b>Objective</b> We describe the first jugular foramen angiomatoid fibrous histiocytoma (AFH) case and the first treatment with preoperative endovascular embolization. AFH is a rare intracranial neoplasm, primarily found in pediatric patient extremities. With an increase in AFH awareness and a well-described genetic profile, intracranial prevalence has also subsequently increased. <b>Study Design</b> We compare this case to previously reported cases using PubMed/Medline literature search, which was performed using the algorithm [\"intracranial\" AND \"angiomatoid fibrous histiocytoma\"] through December 2020 (23 manuscripts with 46 unique cases). <b>Patient</b> An 8-year-old female presented with failure to thrive and right-sided hearing loss. Work-up revealed an absence of right-sided serviceable hearing and a large jugular foramen mass. Angiogram revealed primary arterial supply from the posterior branch of the ascending pharyngeal artery, which was preoperatively embolized. <b>Intervention</b> Gross total resection was performed via a translabyrinthine approach. <b>Conclusion</b> The case presented is unique; the first reported AFH at the jugular foramen and the first reported case utilizing preoperative embolization. Preoperative embolization is a relatively safe technique that can improve the surgeon's ability to perform a maximally safe resection, which may decrease the need for adjuvant radiation in rare skull base tumors in young patients.</p>","PeriodicalId":44256,"journal":{"name":"Journal of Neurological Surgery Reports","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e5/9a/10-1055-s-0042-1754320.PMC9489471.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33478431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-13eCollection Date: 2022-07-01DOI: 10.1055/s-0042-1755599
Sukaina Hasnie, Chad Glenn, Jo E G Peterson, Edward T El Rassi, Kibwei A McKinney
Introduction Biphenotypic sinonasal sarcoma (BSNS) is a recently found entity that first described by Lewis et al. It was then added to the 4th edition of the World Health Organization (WHO) of head and neck tumors in 2012. BSNS has been described as a rare low-grade sarcoma arising in the upper sinonasal tract. It is believed that in the past, BSNS was, likely, previously diagnosed as other low-grade or benign malignancies. Fibrosarcoma, leiomyosarcoma, and peripheral nerve sheath tumors, all fall within the differential diagnosis of BSNS. However, BSNS is unlike other mesenchymal sinonasal tumors, as it displays both neural and myogenic differentiation. BSNS has thus far been recognized in only a hand full of case reports, all of which have reported similar morphologic features of a low-grade soft tissue tumor with neural involvement arising from the nasal cavity or ethmoid air cells in middle aged individuals. In fact, being low-grade sarcoma became such a hallmark characteristic of this tumor that it even received the name low-grade sinonasal sarcoma with neural and myogenic features or LGSSNMF. Case Presentation We present, however, for the first time, a high-grade differentiation of BSNS in an otherwise healthy 72-year-old female. The patient was referred from an outside ENT (ear, nose, and throat) after pathology from a presumed polypectomy returned positive for a BSNS. Initial imaging revealed erosion through the bilateral lamina papyracea, anterior cranial fossa floor, and posterior table of the frontal sinus. She then underwent a combined endoscopic and bicoronal open approach for resection of the skull base lesion that was found to encompass the entirety of the sinonasal cavities bilaterally. Postoperatively, the patient underwent significant complications including infection of the pericranial flap, pneumocephalus, and eventually death. Discussion As BSNS is a fairly new entity, currently there has only been four case series conducted, each identifying features of a low-grade sarcoma with both myogenic and neural differentiation. Histologically, BSNS has monophasic spindle cells with uniform, elongated nuclei with scant cytoplasm between benign proliferations of surface-type respiratory epithelium, with a low mitotic rate. Our case, however, revealed pleomorphic hyperchromatic cells with high mitotic activity and necrosis with invasion of bone, staging it as high grade. Immunohistochemistry also differed from the previously reported standards. This case describes a new category for BSNS which may change the differential diagnosis, management, and surgical recommendations that are currently utilized for this skull base neoplasm.
{"title":"High-Grade Biphenotypic Sinonasal Sarcoma: A Case Report.","authors":"Sukaina Hasnie, Chad Glenn, Jo E G Peterson, Edward T El Rassi, Kibwei A McKinney","doi":"10.1055/s-0042-1755599","DOIUrl":"https://doi.org/10.1055/s-0042-1755599","url":null,"abstract":"<p><p><b>Introduction</b> Biphenotypic sinonasal sarcoma (BSNS) is a recently found entity that first described by Lewis et al. It was then added to the 4th edition of the World Health Organization (WHO) of head and neck tumors in 2012. BSNS has been described as a rare low-grade sarcoma arising in the upper sinonasal tract. It is believed that in the past, BSNS was, likely, previously diagnosed as other low-grade or benign malignancies. Fibrosarcoma, leiomyosarcoma, and peripheral nerve sheath tumors, all fall within the differential diagnosis of BSNS. However, BSNS is unlike other mesenchymal sinonasal tumors, as it displays both neural and myogenic differentiation. BSNS has thus far been recognized in only a hand full of case reports, all of which have reported similar morphologic features of a low-grade soft tissue tumor with neural involvement arising from the nasal cavity or ethmoid air cells in middle aged individuals. In fact, being low-grade sarcoma became such a hallmark characteristic of this tumor that it even received the name low-grade sinonasal sarcoma with neural and myogenic features or LGSSNMF. <b>Case Presentation</b> We present, however, for the first time, a high-grade differentiation of BSNS in an otherwise healthy 72-year-old female. The patient was referred from an outside ENT (ear, nose, and throat) after pathology from a presumed polypectomy returned positive for a BSNS. Initial imaging revealed erosion through the bilateral lamina papyracea, anterior cranial fossa floor, and posterior table of the frontal sinus. She then underwent a combined endoscopic and bicoronal open approach for resection of the skull base lesion that was found to encompass the entirety of the sinonasal cavities bilaterally. Postoperatively, the patient underwent significant complications including infection of the pericranial flap, pneumocephalus, and eventually death. <b>Discussion</b> As BSNS is a fairly new entity, currently there has only been four case series conducted, each identifying features of a low-grade sarcoma with both myogenic and neural differentiation. Histologically, BSNS has monophasic spindle cells with uniform, elongated nuclei with scant cytoplasm between benign proliferations of surface-type respiratory epithelium, with a low mitotic rate. Our case, however, revealed pleomorphic hyperchromatic cells with high mitotic activity and necrosis with invasion of bone, staging it as high grade. Immunohistochemistry also differed from the previously reported standards. This case describes a new category for BSNS which may change the differential diagnosis, management, and surgical recommendations that are currently utilized for this skull base neoplasm.</p>","PeriodicalId":44256,"journal":{"name":"Journal of Neurological Surgery Reports","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9d/8c/10-1055-s-0042-1755599.PMC9470382.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40361868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-08-25eCollection Date: 2022-07-01DOI: 10.1055/a-1858-7628
Jose E Valerio, Sebastian Ochoa, Sandra Alvarez, Matteo Borro, Andres M Alvarez-Pinzon
Introduction In 2017, the U.S. Food and Drug Administration (FDA) approved 5-aminolevulinic acid (5-ALA) as an intraoperative optical imaging agent in patients with suspected high-grade gliomas (HGGs). However, the application of 5-ALA for low-grade gliomas is still less accepted. Astrocytoma, isocitrate dehydrogenase (IDH) mutant tumors are diffuse infiltrating astrocytic tumors where there is no identifiable border between the tumor and normal brain tissue, even though the borders may appear relatively well-marginated on imaging. Generally, it is considered that 5-ALA cannot pass through a normal blood-brain barrier (BBB). Thus, 5-ALA fluorescence may mean disruption of BBB in grade II glioma. Case Report A 74-year-old male patient was diagnosed with a right parietal lesion suggestive of a low-grade brain tumor in a surgical resection using 5-ALA, which led to the detection of tiny fluorescence spots during the surgery. The frozen section was consistent with diffuse astrocytoma, IDH-wildtype (World Health Organization [WHO] grade II). The patient's postoperative magnetic resonance imaging (MRI) showed complete resection. Eight months after surgery, he began experiencing symptoms again and was admitted with a brain MRI finding consistent with recurrent infiltrating astrocytomas. This required reoperation of the brain tumor resection with 5-ALA. Unlike the first surgery, they observed a high fluorescence intensity; the pathological finding was glioblastoma, IDH-wildtype (WHO grade IV). Postsurgical brain MRI showed total resection of the tumor. The patient was discharged 4 weeks after surgery and continued with specialized clinical follow-up. Conclusion The use of 5-ALA continues to be a great contributor to the improvement in complete resection of primary brain tumors, especially HGG. Besides, fluorescence is increasingly approaching its use as a prognostic tool for aggressive clinical course, regardless of the initial grade of the tumor. This case report is an effort to expand knowledge for potentially using 5-ALA to help prognosticate brain tumors. Nevertheless, more clinical prospective studies must be conducted.
2017年,美国食品和药物管理局(FDA)批准5-氨基乙酰丙酸(5-ALA)作为疑似高级别胶质瘤(HGGs)患者的术中光学显像剂。然而,5-ALA在低级别胶质瘤中的应用仍然较少被接受。星形细胞瘤,异柠檬酸脱氢酶(IDH)突变肿瘤是弥漫性浸润性星形细胞肿瘤,肿瘤与正常脑组织之间没有可识别的边界,尽管在成像上边界可能相对较好。一般认为5-ALA不能通过正常血脑屏障(BBB)。因此,5-ALA荧光可能意味着II级胶质瘤中血脑屏障的破坏。病例报告一例74岁男性患者在5-ALA手术切除时被诊断为右脑顶叶病变提示低级别脑肿瘤,术中发现微小荧光斑点。冷冻切片符合弥漫性星形细胞瘤,IDH-wildtype (World Health Organization [WHO] grade II)。患者术后磁共振成像(MRI)显示完全切除。手术后8个月,他再次出现症状,并因脑部MRI发现与复发性浸润性星形细胞瘤一致而入院。这需要用5-ALA再手术切除脑肿瘤。与第一次手术不同,他们观察到高荧光强度;病理表现为胶质母细胞瘤,idh -野生型(WHO分级IV级)。术后脑MRI显示肿瘤全切除。术后4周出院,继续专科临床随访。结论5-ALA的应用对原发性脑肿瘤,尤其是HGG的完全切除有很大的促进作用。此外,无论肿瘤的初始分级如何,荧光越来越多地被用作侵袭性临床病程的预后工具。本病例报告是一项努力,以扩大知识的潜在使用5-ALA,以帮助预测脑肿瘤。然而,必须进行更多的临床前瞻性研究。
{"title":"5-Aminolevulinic Acid-A Biomarker for Worse Prognosis in IDH-Wildtype II Tumors? Evolution of a Fluorescence-Positive Diffuse Astrocytoma: A Case Report.","authors":"Jose E Valerio, Sebastian Ochoa, Sandra Alvarez, Matteo Borro, Andres M Alvarez-Pinzon","doi":"10.1055/a-1858-7628","DOIUrl":"https://doi.org/10.1055/a-1858-7628","url":null,"abstract":"<p><p><b>Introduction</b> In 2017, the U.S. Food and Drug Administration (FDA) approved 5-aminolevulinic acid (5-ALA) as an intraoperative optical imaging agent in patients with suspected high-grade gliomas (HGGs). However, the application of 5-ALA for low-grade gliomas is still less accepted. Astrocytoma, isocitrate dehydrogenase (IDH) mutant tumors are diffuse infiltrating astrocytic tumors where there is no identifiable border between the tumor and normal brain tissue, even though the borders may appear relatively well-marginated on imaging. Generally, it is considered that 5-ALA cannot pass through a normal blood-brain barrier (BBB). Thus, 5-ALA fluorescence may mean disruption of BBB in grade II glioma. <b>Case Report</b> A 74-year-old male patient was diagnosed with a right parietal lesion suggestive of a low-grade brain tumor in a surgical resection using 5-ALA, which led to the detection of tiny fluorescence spots during the surgery. The frozen section was consistent with diffuse astrocytoma, IDH-wildtype (World Health Organization [WHO] grade II). The patient's postoperative magnetic resonance imaging (MRI) showed complete resection. Eight months after surgery, he began experiencing symptoms again and was admitted with a brain MRI finding consistent with recurrent infiltrating astrocytomas. This required reoperation of the brain tumor resection with 5-ALA. Unlike the first surgery, they observed a high fluorescence intensity; the pathological finding was glioblastoma, IDH-wildtype (WHO grade IV). Postsurgical brain MRI showed total resection of the tumor. The patient was discharged 4 weeks after surgery and continued with specialized clinical follow-up. <b>Conclusion</b> The use of 5-ALA continues to be a great contributor to the improvement in complete resection of primary brain tumors, especially HGG. Besides, fluorescence is increasingly approaching its use as a prognostic tool for aggressive clinical course, regardless of the initial grade of the tumor. This case report is an effort to expand knowledge for potentially using 5-ALA to help prognosticate brain tumors. Nevertheless, more clinical prospective studies must be conducted.</p>","PeriodicalId":44256,"journal":{"name":"Journal of Neurological Surgery Reports","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cc/e8/10-1055-a-1858-7628.PMC9411034.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33442356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-19eCollection Date: 2022-07-01DOI: 10.1055/a-1847-8245
William C Broaddus, Aravind Somasundaram, Matthew T Carr, Charles F Opalak, Hope T Richard, Sharon B Wolber, Hayri E Sangiray
Introduction Langerhans cell histiocytosis (LCH) is a rare disease that encompasses a spectrum of clinical syndromes. It is characterized by the proliferation and infiltration of white blood cells into organs or organ systems. Reports of management of these lesions have included biopsy, resection, curettage, radiation, and/or chemotherapy. Case Presentation A 40-year-old man presented with a history of right proptosis and retro-orbital pain and was found to have a lytic mass involving the greater wing of the sphenoid extending into the right orbit. A stereotactic needle biopsy using neuronavigation demonstrated this to be LCH. After no further treatment, the mass spontaneously resolved, with virtual normalization of the orbital magnetic resonance imaging at 10 months following the needle biopsy. The bony defect of the temporal bone caused by the mass also re-ossified following the needle biopsy. Discussion This report highlights the potential for an isolated LCH lesion to regress after simple needle biopsy, an outcome only rarely reported previously. Thus, expectant management of such lesions following biopsy or initial debridement should be considered prior to proceeding with additional treatment.
{"title":"Resolution and Re-ossification of Orbital-Wall Langerhans Cell Histiocytosis Following Stereotactic Needle Biopsy.","authors":"William C Broaddus, Aravind Somasundaram, Matthew T Carr, Charles F Opalak, Hope T Richard, Sharon B Wolber, Hayri E Sangiray","doi":"10.1055/a-1847-8245","DOIUrl":"https://doi.org/10.1055/a-1847-8245","url":null,"abstract":"<p><p><b>Introduction</b> Langerhans cell histiocytosis (LCH) is a rare disease that encompasses a spectrum of clinical syndromes. It is characterized by the proliferation and infiltration of white blood cells into organs or organ systems. Reports of management of these lesions have included biopsy, resection, curettage, radiation, and/or chemotherapy. <b>Case Presentation</b> A 40-year-old man presented with a history of right proptosis and retro-orbital pain and was found to have a lytic mass involving the greater wing of the sphenoid extending into the right orbit. A stereotactic needle biopsy using neuronavigation demonstrated this to be LCH. After no further treatment, the mass spontaneously resolved, with virtual normalization of the orbital magnetic resonance imaging at 10 months following the needle biopsy. The bony defect of the temporal bone caused by the mass also re-ossified following the needle biopsy. <b>Discussion</b> This report highlights the potential for an isolated LCH lesion to regress after simple needle biopsy, an outcome only rarely reported previously. Thus, expectant management of such lesions following biopsy or initial debridement should be considered prior to proceeding with additional treatment.</p>","PeriodicalId":44256,"journal":{"name":"Journal of Neurological Surgery Reports","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/22/3b/10-1055-a-1847-8245.PMC9296262.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40543633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-12eCollection Date: 2022-04-01DOI: 10.1055/a-1830-2236
Otávio da Cunha Ferreira Neto, Débora Mendes Braun, Artêmio José Araruna Dias, Nilson Batista Lemos, Andrey Maia Silva Diniz, Luís Felipe Gonçalves de Lima, Joaquim Fechine de Alencar Neto, Bianca Domiciano Vieira Costa Cabral, Jonas Silva Andrade, Rafaelly Maia Clemente, Luiz Severo Bem Bem Junior, Nivaldo Sena Almeida, Hildo Rocha Cirne Azevedo Filho
Craniopharyngioma is a rare embryonic malformation, usually benign, of the sellar or parasellar regions. In this study, an uncommon case of third ventricle craniopharyngioma and a succinct review of its prevalence are presented. Even with low mortality rates, these injuries involve a high degree of endocrinological, visual, and neuropsychological morbidities, which have a huge impact on the patient's quality of life. Thus, surgical resection is the preferred therapy for tumors that compromise the flow of cerebrospinal fluid. However, due to the location of the craniopharyngioma, surgical management is accompanied by the risk of injury to important adjacent areas with postoperative repercussions. Therefore, the neurosurgeon's experience and the choice of the best surgical approach, are crucial for increasing prognosis.
{"title":"Third Ventricle Craniopharyngioma Intraventricular Tumor: A Case Report and a Brief Literature Review.","authors":"Otávio da Cunha Ferreira Neto, Débora Mendes Braun, Artêmio José Araruna Dias, Nilson Batista Lemos, Andrey Maia Silva Diniz, Luís Felipe Gonçalves de Lima, Joaquim Fechine de Alencar Neto, Bianca Domiciano Vieira Costa Cabral, Jonas Silva Andrade, Rafaelly Maia Clemente, Luiz Severo Bem Bem Junior, Nivaldo Sena Almeida, Hildo Rocha Cirne Azevedo Filho","doi":"10.1055/a-1830-2236","DOIUrl":"https://doi.org/10.1055/a-1830-2236","url":null,"abstract":"<p><p>Craniopharyngioma is a rare embryonic malformation, usually benign, of the sellar or parasellar regions. In this study, an uncommon case of third ventricle craniopharyngioma and a succinct review of its prevalence are presented. Even with low mortality rates, these injuries involve a high degree of endocrinological, visual, and neuropsychological morbidities, which have a huge impact on the patient's quality of life. Thus, surgical resection is the preferred therapy for tumors that compromise the flow of cerebrospinal fluid. However, due to the location of the craniopharyngioma, surgical management is accompanied by the risk of injury to important adjacent areas with postoperative repercussions. Therefore, the neurosurgeon's experience and the choice of the best surgical approach, are crucial for increasing prognosis.</p>","PeriodicalId":44256,"journal":{"name":"Journal of Neurological Surgery Reports","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d1/8b/10-1055-a-1830-2236.PMC9276335.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40595384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-10eCollection Date: 2022-07-01DOI: 10.1055/s-0042-1750366
Cylaina E Bird, Jeffrey I Traylor, Zachary D Johnson, Jun Kim, Jack Raisanen, Babu G Welch, Kalil G Abdullah
Intraosseous hemangiomas are rare, benign tumors that can arise from the calvarium. These lesions often invade the outer table of the skull, but typically spare the inner table and intracranial structures. En bloc surgical resection is the standard treatment for intraosseous hemangiomas. However, a piecemeal resection may be required to safely remove the tumor in cases involving the inner table to protect the underlying brain parenchyma and vascular structures. Proper reconstruction is critical to optimize the cosmetic outcome, and a staged procedure allowing implantation of a custom-made implant can be considered for large lesions involving the forehead. We present a case of a patient with a large frontal intraosseous hemangioma with intradural involvement to highlight the surgical nuances of resection and review the existing literature regarding optimal management of these patients.
{"title":"Surgical Management of a Massive Frontal Bone Hemangioma: Case Report.","authors":"Cylaina E Bird, Jeffrey I Traylor, Zachary D Johnson, Jun Kim, Jack Raisanen, Babu G Welch, Kalil G Abdullah","doi":"10.1055/s-0042-1750366","DOIUrl":"https://doi.org/10.1055/s-0042-1750366","url":null,"abstract":"<p><p>Intraosseous hemangiomas are rare, benign tumors that can arise from the calvarium. These lesions often invade the outer table of the skull, but typically spare the inner table and intracranial structures. En bloc surgical resection is the standard treatment for intraosseous hemangiomas. However, a piecemeal resection may be required to safely remove the tumor in cases involving the inner table to protect the underlying brain parenchyma and vascular structures. Proper reconstruction is critical to optimize the cosmetic outcome, and a staged procedure allowing implantation of a custom-made implant can be considered for large lesions involving the forehead. We present a case of a patient with a large frontal intraosseous hemangioma with intradural involvement to highlight the surgical nuances of resection and review the existing literature regarding optimal management of these patients.</p>","PeriodicalId":44256,"journal":{"name":"Journal of Neurological Surgery Reports","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6b/21/10-1055-s-0042-1750366.PMC9272017.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40504056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-10eCollection Date: 2022-07-01DOI: 10.1055/s-0042-1750291
Grace E O'Shea, Victoria L Watson, Leslie Acakpo-Satchivi
Cranial dermoids have the tendency to occur in the midline, especially near fontanelles and sutures early in the life of a patient. Here we present an unusual case of an intraosseous dermoid that presented initially as a lytic lesion, off of the midline and not associated with cranial sutures or fontanelles. The diameter of the lesion grew to approx 15 mm over time, thus the decision was made to take the child to surgery for removal of dermoid with the use of neuronavigation and cranioplasty. A dermoid cyst was confirmed on histopathologic analysis.
{"title":"Intraosseous Dermoid Presenting as an Expansile Lytic Lesion.","authors":"Grace E O'Shea, Victoria L Watson, Leslie Acakpo-Satchivi","doi":"10.1055/s-0042-1750291","DOIUrl":"https://doi.org/10.1055/s-0042-1750291","url":null,"abstract":"<p><p>Cranial dermoids have the tendency to occur in the midline, especially near fontanelles and sutures early in the life of a patient. Here we present an unusual case of an intraosseous dermoid that presented initially as a lytic lesion, off of the midline and not associated with cranial sutures or fontanelles. The diameter of the lesion grew to approx 15 mm over time, thus the decision was made to take the child to surgery for removal of dermoid with the use of neuronavigation and cranioplasty. A dermoid cyst was confirmed on histopathologic analysis.</p>","PeriodicalId":44256,"journal":{"name":"Journal of Neurological Surgery Reports","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6e/9c/10-1055-s-0042-1750291.PMC9272015.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40504057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-10eCollection Date: 2022-07-01DOI: 10.1055/s-0042-1753519
Emily E Karp, Jamie J Van Gompel, Garret Choby
Esthesioneuroblastoma is a rare malignancy originating from the olfactory epithelium. Treatment consists of surgical resection with strong consideration for adjuvant treatment in advanced Kadish stage and high Hyams grade. In the modern era, overall outcomes for esthesioneuroblastoma are favorable compared with many other sinonasal malignancies with 5-year overall survival estimated to be 80%. When selecting the optimal surgical approach, the surgeon must consider the approach that will allow for a negative margin resection and adequate reconstruction. In appropriately selected patients, endoscopic outcomes appear at least equivalent to open approaches and unilateral endoscopic approach may be used in select olfactory preservation cases.
{"title":"Esthesioneuroblastoma (Olfactory Neuroblastoma): Overview and Extent of Surgical Approach and Skull Base Resection.","authors":"Emily E Karp, Jamie J Van Gompel, Garret Choby","doi":"10.1055/s-0042-1753519","DOIUrl":"https://doi.org/10.1055/s-0042-1753519","url":null,"abstract":"<p><p>Esthesioneuroblastoma is a rare malignancy originating from the olfactory epithelium. Treatment consists of surgical resection with strong consideration for adjuvant treatment in advanced Kadish stage and high Hyams grade. In the modern era, overall outcomes for esthesioneuroblastoma are favorable compared with many other sinonasal malignancies with 5-year overall survival estimated to be 80%. When selecting the optimal surgical approach, the surgeon must consider the approach that will allow for a negative margin resection and adequate reconstruction. In appropriately selected patients, endoscopic outcomes appear at least equivalent to open approaches and unilateral endoscopic approach may be used in select olfactory preservation cases.</p>","PeriodicalId":44256,"journal":{"name":"Journal of Neurological Surgery Reports","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/18/1c/10-1055-s-0042-1753519.PMC9272014.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40504055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-10eCollection Date: 2022-07-01DOI: 10.1055/a-1865-6801
Alex J Gordon, Michael R Papazian, Michael Chow, Aneek Patel, Dimitris G Placantonakis, Seth Lieberman, Babak Givi
Sinonasal glomangiopericytoma is a rare vascular tumor of the respiratory epithelium. Treatment consists mainly of surgical resection, though there is no consensus regarding the use of adjuvant therapies or preoperative endovascular embolization. The postsurgical prognosis is favorable, though there is a high risk of delayed recurrence. Here, we present the case of a patient who underwent endoscopic resection of a sinonasal glomangiopericytoma and a review of the literature.
{"title":"Sinonasal Glomangiopericytoma with Prolonged Postsurgical Follow-Up.","authors":"Alex J Gordon, Michael R Papazian, Michael Chow, Aneek Patel, Dimitris G Placantonakis, Seth Lieberman, Babak Givi","doi":"10.1055/a-1865-6801","DOIUrl":"https://doi.org/10.1055/a-1865-6801","url":null,"abstract":"<p><p>Sinonasal glomangiopericytoma is a rare vascular tumor of the respiratory epithelium. Treatment consists mainly of surgical resection, though there is no consensus regarding the use of adjuvant therapies or preoperative endovascular embolization. The postsurgical prognosis is favorable, though there is a high risk of delayed recurrence. Here, we present the case of a patient who underwent endoscopic resection of a sinonasal glomangiopericytoma and a review of the literature.</p>","PeriodicalId":44256,"journal":{"name":"Journal of Neurological Surgery Reports","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/52/e4/10-1055-a-1865-6801.PMC9272016.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40504053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}